Literature DB >> 19666989

The role of human UDP-glucuronyltransferases on the formation of the methylenedioxymethamphetamine (ecstasy) phase II metabolites R- and S-3-methoxymethamphetamine 4-O-glucuronides.

Andrea E Schwaninger1, Markus R Meyer, Josef Zapp, Hans H Maurer.   

Abstract

Different pharmacokinetic properties have been observed for the two enantiomers of the entactogen 3,4-methylendioxy-methamphetamine, most probably a result of enantioselective metabolism. The aim of the present work was to study the involvement of human UDP-glucuronyltransferase (UGT) isoforms in the glucuronidation of the enantiomers of its major metabolite 4-hydroxy-3-methoxymethamphetamine (HMMA). First, the reference standards of R- and S-HMMA-O-glucuronide were synthesized semipreparatively using the enzymes of rat liver microsomes, followed by isolation with semipreparative high-performance liquid chromatography and identification using mass spectrometry and NMR. Racemic HMMA was then incubated using heterologously expressed human UGTs and pooled human liver microsomes (HLMs), and the glucuronides were quantified by liquid chromatography-linear ion trap-mass spectrometry. UGT1A1, UGT1A3, UGT1A8, UGT1A9, UGT2B4, UGT2B7, UGT2B15, and UGT2B17 were involved in the glucuronidation of HMMA. UGT2B15, UGT2B17, and HLM revealed classic Michaelis-Menten kinetics, whereas UGT1A9 and UGT2B7 showed sigmoidal curves and the respective Eadie-Hofstee plots indicated autoactivation kinetics. UGT2B15 showed the highest affinity and activity. UGT2B15, UGT2B17, and HLMs were not considerably enantioselective but showed slight preferences for S-HMMA. Marked enantioselectivity could only be observed for UGT1A9 with respect to the S-enantiomer and for UGT2B7 with respect to the R-enantiomer. In conclusion, the O-glucuronidation of HMMA in vivo should not be expected to be enantioselective, and the different pharmacokinetic properties may not be caused directly by glucuronidation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19666989     DOI: 10.1124/dmd.109.029215

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Rapid quantitative chiral amphetamines liquid chromatography-tandem mass spectrometry: method in plasma and oral fluid with a cost-effective chiral derivatizing reagent.

Authors:  Matthew N Newmeyer; Marta Concheiro; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2014-07-05       Impact factor: 4.759

2.  Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans.

Authors:  Andrea E Schwaninger; Markus R Meyer; Allan J Barnes; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis; Hans H Maurer
Journal:  Biochem Pharmacol       Date:  2011-09-29       Impact factor: 5.858

3.  Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.

Authors:  Andrea E Schwaninger; Markus R Meyer; Allan J Barnes; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis; Hans H Maurer
Journal:  Clin Chem       Date:  2011-10-06       Impact factor: 8.327

4.  Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine.

Authors:  Andrea E Schwaninger; Markus R Meyer; Marilyn A Huestis; Hans H Maurer
Journal:  J Mass Spectrom       Date:  2011-07       Impact factor: 1.982

5.  Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.

Authors:  Andrea E Steuer; Corina Schmidhauser; Eva H Tingelhoff; Yasmin Schmid; Anna Rickli; Thomas Kraemer; Matthias E Liechti
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.